Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.
Novartis secures pair of regulatory wins for skin disease and malaria treatments
Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.
Despite being widely used by gym-goers, even one popular supplement has its limitations, according to new research.
More than 40 million Americans are already opting to take on the cost of sick visits, drugs and surgeries to get lower premiums and tax savings.
Homeland Security Secretary Markwayne Mullin on Sunday said the Cybersecurity and Infrastructure Security Agency (CISA) lost about 1,100 employees over the course of the partial government …
يُعد نقص الفولات الدماغي من الاضطرابات النادرة التي قد تبدأ بصمت ثم تتحول إلى مشكلة عصبية معقدة تؤثر على نمو الطفل. علاج هذه الحالة مبكرًا قد …